Clinical improvement · patients with induction of remission in ulcerative colitis
It is very uncertain whether UFH changes clinical improvement compared with corticosteroids (very low certainty).
1 finding from 1 review
Maternal death · women with varicose veins before birth, having a caesarean (elective or emergency) or vaginal birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic thromboembolic events ( · women with varicose veins before birth, having a caesarean (elective or emergency) or vaginal birth
It is very uncertain whether peripartum/postnatal prophylaxis: UFH changes symptomatic thromboembolic events ( compared with no treatment (very low certainty).
1 finding from 1 review
Symptomatic PE · women with varicose veins before birth, having a caesarean (elective or emergency) or vaginal birth
It is very uncertain whether peripartum/postnatal prophylaxis: UFH changes symptomatic PE ( compared with no treatment (very low certainty).
1 finding from 1 review
Symptomatic DVT · women with varicose veins before birth, having a caesarean (elective or emergency) or vaginal birth
It is very uncertain whether peripartum/postnatal prophylaxis: UFH changes symptomatic DVT ( compared with no treatment (very low certainty).
1 finding from 1 review
Adverse effects sufficient to stop treatment · women with varicose veins before birth, having a caesarean (elective or emergency) or vaginal birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maternal death · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic thromboembolic events ( · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic thromboembolic events ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic PE · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic PE ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic DVT · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic DVT ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Adverse effects sufficient to stop treatment · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes adverse effects sufficient to stop treatment compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Maternal death · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review
Symptomatic thromboembolic events ( · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic thromboembolic events (timing of assessment unclear,… compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic PE · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic PE (timing of assessment unclear, within 6 weeks… compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic DVT · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review
Adverse effects sufficient to stop treatment · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review
All causes of mortality at 30 days ‐ UFH · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in all causes of mortality at 30 days ‐ UFH compared with anticoagulants (high certainty).
1 finding from 1 review
Major bleeding · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in major bleeding at 30 days ‐ UFH compared with anticoagulants (high certainty).
1 finding from 1 review
Minor bleeding · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in minor bleeding at 30 days ‐ UFH compared with anticoagulants (moderate certainty).
1 finding from 1 review
Adverse effects sufficient to stop treatment · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: LMWH changes adverse effects sufficient to stop treatment compared with UFH (very low certainty).
1 finding from 1 review